Cargando…

Mechanisms of ADAMTS13 regulation

Recombinant ADAMTS13 is currently undergoing clinical trials as a treatment for hereditary thrombotic thrombocytopenic purpura, a lethal microvascular condition resulting from ADAMTS13 deficiency. Preclinical studies have also demonstrated its efficacy in treating arterial thrombosis and inflammatio...

Descripción completa

Detalles Bibliográficos
Autores principales: DeYoung, Veronica, Singh, Kanwal, Kretz, Colin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826392/
https://www.ncbi.nlm.nih.gov/pubmed/36074019
http://dx.doi.org/10.1111/jth.15873